4D Molecular Therapeutics FDMT Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's operating lease right-of-use asset amortization?
- 4D Molecular Therapeutics (FDMT) reported operating lease right-of-use asset amortization of $786K in Q1 2026.
- How has 4D Molecular Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
- 4D Molecular Therapeutics's operating lease right-of-use asset amortization increased by 11.8% year-over-year, from $703K to $786K.
- What is the long-term trend for 4D Molecular Therapeutics's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's operating lease right-of-use asset amortization has grown at a 18.3% compound annual growth rate (CAGR), from $1.5M to $2.93M.